Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Thursday 19 May, 2011

Summit Corporation PLC

AGM Statement






Summit Corporation plc
("Summit" or "the Company")


RESULT OF ANNUAL GENERAL MEETING

Oxford, UK, 19 May 2011, Summit Corporation plc (AIM: SUMM), a UK drug discovery
company, announces the results from its Annual General Meeting ('AGM') that was
held today.  Of the five resolutions that that were proposed to shareholders,
all were duly passed.  The results of the proxy votes lodged in advance of the
AGM will be available on Summit's website shortly.

In addition, a presentation and accompanying statement given by the Executive
Chairman of Summit, Dr Barry Price, is available from the Investors section of
the Company website or on request to investors@summitplc.com.

                                    - END -

For more information, please contact:

 Summit

 Barry Price, PhD

 Richard Pye, PhD                             Tel: +44 (0)1235 443939



 Singer Capital Markets (Nominated Adviser)

 Shaun Dobson / Claes Spång                   Tel: +44 (0)20 3205 7500



 Peckwater PR

 Tarquin  Edwards                             Tel: +44 (0)7879 458 364
                                              tarquin.edwards@peckwaterpr.co.uk



About Summit
Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins(TM) for the discovery of new medicines, a
portfolio of drug programme assets and a commercial strategy of signing multiple
early-stage deals.

Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in the high-value therapy areas and the
Company will further exploit the technology's wider potential through strategic
alliances.  Summit's programme portfolio consists of a number of drug programmes
targeting high-value areas of unmet medical need including Duchenne Muscular
Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, remove
development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available at www.summitplc.com.






This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Summit Corporation PLC via Thomson Reuters ONE

[HUG#1517163]